A detailed history of Avalon Investment & Advisory transactions in Eli Lilly & CO stock. As of the latest transaction made, Avalon Investment & Advisory holds 62,151 shares of LLY stock, worth $49.5 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
62,151
Previous 63,694 2.42%
Holding current value
$49.5 Million
Previous $23.3 Million 8.41%
% of portfolio
0.6%
Previous 0.66%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$310.63 - $364.82 $479,302 - $562,917
-1,543 Reduced 2.42%
62,151 $21.3 Million
Q4 2022

Feb 13, 2023

BUY
$321.55 - $374.67 $20.5 Million - $23.9 Million
63,694 New
63,694 $23.3 Million
Q2 2021

Jul 29, 2021

SELL
$180.55 - $233.54 $812,475 - $1.05 Million
-4,500 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$164.32 - $212.72 $295,776 - $382,896
-1,800 Reduced 28.57%
4,500 $841,000
Q4 2020

Feb 08, 2021

SELL
$130.46 - $172.63 $94,713 - $125,329
-726 Reduced 10.33%
6,300 $1.06 Million
Q3 2020

Nov 04, 2020

SELL
$146.22 - $169.13 $22,371 - $25,876
-153 Reduced 2.13%
7,026 $1.04 Million
Q2 2020

Aug 07, 2020

SELL
$136.42 - $164.18 $68,073 - $81,925
-499 Reduced 6.5%
7,179 $1.18 Million
Q1 2020

May 05, 2020

SELL
$119.05 - $147.35 $543,344 - $672,505
-4,564 Reduced 37.28%
7,678 $1.07 Million
Q4 2019

Feb 14, 2020

SELL
$106.92 - $132.43 $2,673 - $3,310
-25 Reduced 0.2%
12,242 $1.61 Million
Q3 2019

Nov 14, 2019

SELL
$106.79 - $116.16 $744,646 - $809,983
-6,973 Reduced 36.24%
12,267 $1.37 Million
Q2 2019

Aug 14, 2019

SELL
$110.79 - $129.32 $11.6 Million - $13.5 Million
-104,696 Reduced 84.48%
19,240 $2.13 Million
Q1 2019

Apr 24, 2019

SELL
$111.31 - $131.02 $798,315 - $939,675
-7,172 Reduced 5.47%
123,936 $16.1 Million
Q4 2018

Feb 14, 2019

BUY
$105.9 - $118.64 $3.4 Million - $3.8 Million
32,068 Added 32.38%
131,108 $15.2 Million
Q3 2018

Nov 14, 2018

SELL
$85.86 - $107.31 $14.2 Million - $17.7 Million
-164,897 Reduced 62.48%
99,040 $10.6 Million
Q2 2018

Aug 14, 2018

SELL
$75.7 - $86.88 $755,334 - $866,888
-9,978 Reduced 3.64%
263,937 $22.5 Million
Q1 2018

Jun 26, 2018

BUY
$74.21 - $87.6 $71,612 - $84,534
965 Added 0.35%
273,915 $21.2 Million
Q1 2018

Jun 22, 2018

SELL
$74.21 - $87.6 $632,194 - $746,264
-8,519 Reduced 3.03%
272,950 $23.1 Million
Q1 2018

May 15, 2018

BUY
$74.21 - $87.6 $632,194 - $746,264
8,519 Added 3.12%
281,469 $21.8 Million
Q4 2017

Jun 22, 2018

SELL
$81.94 - $87.89 $1.2 Million - $1.29 Million
-14,681 Reduced 5.1%
272,950 $23.1 Million
Q4 2017

Feb 14, 2018

BUY
$81.94 - $87.89 $3.52 Million - $3.78 Million
42,989 Added 17.57%
287,631 $24.3 Million
Q3 2017

Nov 14, 2017

BUY
$77.07 - $85.54 $132,252 - $146,786
1,716 Added 0.71%
244,642 $20.9 Million
Q2 2017

Aug 14, 2017

BUY
N/A
242,926
242,926 $20 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Avalon Investment & Advisory Portfolio

Follow Avalon Investment & Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avalon Investment & Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Avalon Investment & Advisory with notifications on news.